Last update 01 Jul 2024
iNeo-Vac-P01
Last update 01 Jul 2024
Overview
Basic Info
Drug Type Personalized antigen vaccine, Synthetic peptide vaccine |
Synonyms iNeo Vac P01, Neoantigen peptides vaccine, 肿瘤新生抗原多肽治疗性疫苗 + [3] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Related
11
Clinical Trials associated with iNeo-Vac-P01A single-center, single-arm, open clinical trial of personalized neoantigen peptides vaccine sequential combined with TACE/HAIC, targeted therapy and immunotherapy in the treatment of advanced primary liver cancer
Start Date28 Jan 2023 |
Sponsor / Collaborator- |
A Multicenter, Single-arm, Confirmatory Study to Assess the Safety and Efficacy of Intracranial Cerebral Aneurysm Embolization with G-009 - G-009-P01
Start Date16 Dec 2021 |
Sponsor / Collaborator- |
Clinical Study of a Personalized Neoantigen Vaccine in Esophagus Cancer Patients Who Have Completed Adjuvant Therapy Following Neoadjuvant Therapy and Surgical Resection
This research study is evaluating a new type of esophagus cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for esophagus cancer patients who have completed adjuvant therapy following neoadjuvant therapy and surgical resection. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of resectable esophagus cancer, so as to provide a new personalized therapeutic strategy.
Start Date02 Dec 2021 |
Sponsor / Collaborator |
100 Clinical Results associated with iNeo-Vac-P01
Login to view more data
100 Translational Medicine associated with iNeo-Vac-P01
Login to view more data
100 Patents (Medical) associated with iNeo-Vac-P01
Login to view more data
6
Literatures (Medical) associated with iNeo-Vac-P0101 Jan 2023·Frontiers in pharmacology
Insights into the mechanisms governing P01 scorpion toxin effect against U87 glioblastoma cells oncogenesis.
Article
Author: Srairi-Abid, Najet ; Souid, Soumaya ; Mlayah-Bellalouna, Saoussen ; Vandier, Christophe ; Ayedi, Emna ; Essafi-Benkhadir, Khadija ; Aissaoui-Zid, Dorra ; Mejdoub, Hafedh ; Marrakchi, Naziha ; Chantome, Aurelie ; Belghazi, Maya ; Jebali, Jed
The emerging concept of small conductance Ca2+-activated potassium channels (SKCa) as pharmacological target for cancer treatment has significantly increased in recent years. In this study, we isolated the P01 toxin from Androctonus australis (Aa) scorpion venom and investigated its effect on biological properties of glioblastoma U87, breast MDA-MB231 and colon adenocarcinoma LS174 cancer cell lines. Our results showed that P01 was active only on U87 glioblastoma cells. It inhibited their proliferation, adhesion and migration with IC50 values in the micromolar range. We have also shown that P01 reduced the amplitude of the currents recorded in HEK293 cells expressing SK2 channels with an IC50 value of 3 pM, while it had no effect on those expressing SK3 channels. The investigation of the SKCa channels expression pattern showed that SK2 transcripts were expressed differently in the three cancer cell lines. Particularly, we highlighted the presence of SK2 isoforms in U87 cells, which could explain and rely on the specific activity of P01 on this cell line. These experimental data highlighted the usefulness of scorpion peptides to decipher the role of SKCa channels in the tumorigenesis process, and develop potential therapeutic molecules targeting glioblastoma with high selectivity.
01 Oct 2021·GastroenterologyQ1 · MEDICINE
Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model
Q1 · MEDICINE
Article
Author: Ahadova, Aysel ; Umar, Asad ; Hernandez-Sanchez, Alejandro ; Marshall, Jason D ; Long, Mark ; von Knebel Doeberitz, Magnus ; Sei, Shizuko ; Cortes, Eduardo ; Shoemaker, Robert H ; Urban, Katharina ; Yuan, Yan P ; Lipkin, Steven M ; Liu, Song ; Bork, Peer ; Song, Yurong ; Gelincik, Ozkan ; Edelmann, Winfried ; Deng, Nan ; Katzenmaier, Eva-Maria ; Oezcan-Wahlbrink, Mine ; Kloor, Matthias ; Gebert, Johannes ; Elsaadi, Ali ; Nelius, Nina ; Fuchs, Vera ; Tosti, Elena ; Vilar, Eduardo ; Wei, Lei
BACKGROUND & AIMS:
DNA mismatch repair deficiency drives microsatellite instability (MSI). Cells with MSI accumulate numerous frameshift mutations. Frameshift mutations affecting cancer-related genes may promote tumorigenesis and, therefore, are shared among independently arising MSI tumors. Consequently, such recurrent frameshift mutations can give rise to shared immunogenic frameshift peptides (FSPs) that represent ideal candidates for a vaccine against MSI cancer. Pathogenic germline variants of mismatch repair genes cause Lynch syndrome (LS), a hereditary cancer syndrome affecting approximately 20-25 million individuals worldwide. Individuals with LS are at high risk of developing MSI cancer. Previously, we demonstrated safety and immunogenicity of an FSP-based vaccine in a phase I/IIa clinical trial in patients with a history of MSI colorectal cancer. However, the cancer-preventive effect of FSP vaccination in the scenario of LS has not yet been demonstrated.
METHODS:
A genome-wide database of 488,235 mouse coding mononucleotide repeats was established, from which a set of candidates was selected based on repeat length, gene expression, and mutation frequency. In silico prediction, in vivo immunogenicity testing, and epitope mapping was used to identify candidates for FSP vaccination.
RESULTS:
We identified 4 shared FSP neoantigens (Nacad [FSP-1], Maz [FSP-1], Senp6 [FSP-1], Xirp1 [FSP-1]) that induced CD4/CD8 T cell responses in naïve C57BL/6 mice. Using VCMsh2 mice, which have a conditional knockout of Msh2 in the intestinal tract and develop intestinal cancer, we showed vaccination with a combination of only 4 FSPs significantly increased FSP-specific adaptive immunity, reduced intestinal tumor burden, and prolonged overall survival. Combination of FSP vaccination with daily naproxen treatment potentiated immune response, delayed tumor growth, and prolonged survival even more effectively than FSP vaccination alone.
CONCLUSIONS:
Our preclinical findings support a clinical strategy of recurrent FSP neoantigen vaccination for LS cancer immunoprevention.
01 Sep 2020·Clinical cancer research : an official journal of the American Association for Cancer ResearchQ1 · MEDICINE
A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors
Q1 · MEDICINE
Article
Author: Liu, Liang ; Chen, Shuqing ; Wang, Huina ; Zhang, Shanshan ; Chen, Rongchang ; Chen, Lin ; Zhou, Zhan ; Mo, Fan ; Pan, Hongming ; Wang, Huimin ; Luo, Kai ; Ye, Shengli ; Shou, Jiawei ; Han, Ning ; Li, Hongsen ; Fang, Yong
Abstract:
Purpose::
Because of their high tumor specificity and immunogenicity, neoantigens have been considered as ultimate targets for cancer immunotherapy. Neoantigen-based vaccines have demonstrated promising efficacy for several cancer types. To further investigate the antitumor potentials for other types of solid tumors, we designed a peptide-based neoantigen vaccine, iNeo-Vac-P01, and conducted a single-arm, open-labeled, investigator-initiated clinical trial (NCT03662815).
Patients and Methods::
Personalized neoantigen vaccines were designed and manufactured according to our bioinformatics analysis results from the whole-exome sequencing of tumor and peripheral blood cell DNAs. Patients were scheduled to be vaccinated subcutaneously with adjuvant on days 1, 4, 8, 15, and 22 (prime phase), and days 78 and 162 (boost phase). Additional immunizations were administrated every 2–3 months as per patient's potential benefit. The safety and efficacy were assessed through adverse events (AE), progression-free survival (PFS), overall survival (OS), and other parameters.
Results::
Of the 22 patients enrolled with advanced malignancies, 20 had no or mild AEs, while 2 had grade 3 or 4 acute allergic reactions only after their sixth boost vaccination. The disease control rate was 71.4%. The median PFS was 4.6 months, whereas the median OS was not reached (12-month OS = 55.1%). Around 80% of individual peptides or peptide pools elicited measurable specific immune response. In addition, our findings revealed several potential biomarkers for the prediction of better response.
Conclusions::
iNeo-Vac-P01 as monotherapy is feasible and safe for patients with advanced solid tumors. It could elicit T-cell–mediated immune response targeting tumor neoantigens, and might have promising antitumor efficacy.See related commentary by Filderman and Storkus, p. 4429
2
News (Medical) associated with iNeo-Vac-P0102 Jan 2023
The prevalence of pancreatic cancer has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cancer, the robust pipeline, and the growing research and development activities to develop novel therapies to treat Pancreatic Cancer drive the market. The companies developing the potential therapies in the last stage of development include FibroGen, Eli Lilly and Company, CARsgen Therapeutics, and several others.
LAS VEGAS, Jan. 2, 2023 /PRNewswire/ -- DelveInsight's
'
Pancreatic Cancer Pipeline Insight – 2022
' report provides comprehensive global coverage of available, marketed, and pipeline pancreatic cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the pancreatic cancer pipeline domain.
Key Takeaways from the Pancreatic Cancer Pipeline Report
DelveInsight's pancreatic cancer pipeline report depicts a robust space with
150+ active players working to develop
170+ pipeline therapies for pancreatic cancer treatment.
Key pancreatic cancer companies such as
FibroGen, Innovent Biologics, CARsgen Therapeutics, Ascentage Pharma, NGM Biopharmaceuticals, TME Pharma AG, Lee's Pharmaceutical Limited, ImmunityBio, Inc., Rgene Corporation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CanBas Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, SynerGene Therapeutics, Inc., AbbVie, Silenseed Ltd, Galera Therapeutics, Inc., Helix BioPharma, Golden Biotechnology Corporation, Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd., Panbela Therapeutics, Inc., GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, Roche, Prestige Biopharma Limited, Everfront Biotech Co., Ltd., XBiotech, Inc., Incyte Corporation, Ability Pharmaceuticals SL, Lokon Pharma, HCW Biologics, Amplia Therapeutics Limited, BioLineRx, Ltd., Taiho Pharmaceutical, Sanofi, Scandion Oncology, Nelum, Celldex Therapeutics, Merus N.V., Seagen Inc., GC Cell Corporation, MetiMedi Pharmaceuticals, Lumicell, Nuvation Bio Inc., ENB Therapeutics, BioNTech SE, Bayer, Genentech, Inc., Rise Biopharmaceuticals, Inc., Prestige Biopharma Limited, iOnctura, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Hengrui Pharmaceutical Co., Ltd., Hangzhou Neoantigen Therapeutics Co., Ltd., EUSA Pharma, Inc.,Agenus Inc., Arcus Biosciences, Inc.Amgen, Biomea Fusion, and others are evaluating pancreatic cancer drugs to improve the treatment landscape.
Promising pancreatic cancer pipeline therapies in various stages of development include
Pamrevlumab, Niraparib, CT041, APG-1387, BNT141, ENB003, NUV-868, MCLA-128, LUM015, tisotumab vedotin, OMT-111, tusamitamab ravtansine, SCO-101, NGM120, CDX-301, NLM-001, TAS 102, Olaptesed pegol, BL-8040, Gimatecan, AMP945, N-803, HCW9218, BLEX 404, delolimogene mupadenorepvec, Mitoxantrone Hydrochloride Liposome injection, ABTL0812, CBP501, Pemigatinib, SHR-1701, Fluzoparib, XB2001, Cabiralizumab, EF-009, SGT-53, ABBV-927, PBP1510, Vemurafenib, siG12D-LODER, Penpulimab, GC4711, GSK2256098, L-DOS47, SBP-101, Antroquinonol, LY3214996, Sintilimab, RP72, PBP1510, IOA-289, U87, MVT-5873, SHR-A1904, iNeo-Vac-P01, iNeo-Vac-P01, TQB2858, Siltuximab, AGEN1423, AB680, AMG 199, BMF-219, and others.
In
December 2022,
Targovax ASA announced that it has entered into a
collaboration agreement with
The University of Kansas Cancer Center (KU Cancer Center) and
Agenus Inc. to run a clinical trial testing mutant RAS vaccine TG01 in combination with PD-1 CPI balstilimab in pancreatic cancer following surgery and standard-of-care (SoC) chemotherapy.
In
December 2022,
Bluestar Genomics, Inc. announced the initiation of the
New Onset Diabetes Management for Earlier Detection (NODMED) trial, one of the largest clinical studies in pancreatic cancer to date. The trial will use Bluestar Genomics' proprietary epigenomic methods for the detection of the disease.
In
December 2022,
iOnctura BV, a clinical-stage biotech developing novel cancer therapies, had been granted
€17.5 million ($18.6 million) funding from the
European Investment Council's (EIC) accelerator program to develop
IOA-289 for pancreatic cancer.The EIC's funding consists of a grant of €2.5 million ($2.7 million) and €15 million ($16 million) of equity investment.
In
December 2022, In the Phase I/II
CodeBreaK 100 trial, the KRAS G12C inhibitor
sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer, according to researchers at The University of Texas MD Anderson Cancer Center. The results of the trial, published in the The New England Journal of Medicine, indicate an objective response rate of 21.1% and a median time-to-response of 1.5 months, with 84% of patients experiencing disease control. Median progression-free survival was 4 months, and overall survival was 6.9 months.
In
December 2022,
Oncolytics Biotech® Inc. announced that the U.S.
Food and Drug Administration (FDA) has granted
Fast Track designation to
pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). This represents pelareorep's second FDA Fast Track designation.
In
December 2022,
RemeGen Co., Ltd. announced that its latest antibody-drug conjugate (ADC),
RC118 for injection, has been granted
two orphan drug designations (ODD) by the United States Food and Drug Administration (FDA) for gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer. This marks the Company's fourth, having previously been granted ODD twice for Disitamab Vedotin (RC48) and Telitacicept (RC18) earlier this year.
In
December 2022, Panbela Therapeutics, Inc. announced that the
European Medicines Agency (EMA) Committee for Orphan Medicinal Products issued a positive opinion on Panbela's application for orphan designation of ivospemin (
SBP-101) in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (PDA).
In
September 2022,
Qualigen Therapeutics, Inc. announced the presentation of two posters on
QN-302 at the
AACR 8th Special Conference on Pancreatic Cancer. The data presented include information on the compound's safety, tolerability, and efficacy in a pancreatic cancer model. The poster included preclinical toxicology data that showed QN-302 does not produce adverse toxicological reactions in mouse models at therapeutic doses. In in vitro tests, QN-302 inhibits acetylcholinesterase (AChE) by 53% and muscarinic receptor (M2) by 70% at 1 µM.
Request a sample and discover the recent advances in pancreatic cancer drugs @
Pancreatic Cancer Pipeline Report
The pancreatic cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage pancreatic cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the pancreatic cancer clinical trial landscape.
Pancreatic Cancer Overview
Pancreatic cancer develops in the pancreas tissues, an abdomen organ located behind the stomach's bottom portion. The pancreas secretes hormones that help control blood sugar and enzymes that aid digestion. Pancreatic cancer is a condition in which malignant (cancer) cells develop in pancreatic tissues. The pancreas can develop tumors in various ways, including malignant and noncancerous tumors. However, the precise causes of pancreatic cancer are unknown. Individuals diagnosed with pancreatic cancer before the tumor develops or spreads have an average life expectancy of pancreatic cancer of 3 to 3.5 years.
Pancreatic cancer symptoms may include jaundice, dark urine, weight loss, loss of appetite, fatigue, and others. A pancreatic cancer diagnosis is difficult because symptoms are frequently confused with those of other disorders, such as irritable bowel syndrome. The extent of the cancer determines the treatment of pancreatic cancer options. Pancreatic cancer treatment options may include surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these.
Learn more about the diseases and pancreatic cancer diet @
Pancreatic Cancer Tests
A snapshot of the Pancreatic Cancer Pipeline Drugs mentioned in the report:
Learn more about the emerging pancreatic cancer treatment options @
Pancreatic Cancer Clinical Trials
Pancreatic Cancer Therapeutics Assessment
The
pancreatic cancer pipeline report proffers an integral view of pancreatic cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Pancreatic Cancer Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment
By Route of Administration: Inhalation, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous
Therapeutics Assessment
By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
Therapeutics Assessment
By Mechanism of Action: Connective tissue growth factor inhibitors, Poly(ADP-ribose) polymerase 1 inhibitors, Poly(ADP-ribose) polymerase 2 inhibitors, Immunologic cytotoxicity, T lymphocyte replacements, Growth differentiation factor 15 inhibitors, Endothelin B receptor antagonists, Image enhancers
Key Pancreatic Cancer Companies: FibroGen, Innovent Biologics, CARsgen Therapeutics, Ascentage Pharma, NGM Biopharmaceuticals, TME Pharma AG, Lee's Pharmaceutical Limited, ImmunityBio, Inc., Rgene Corporation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CanBas Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, SynerGene Therapeutics, Inc., AbbVie, Silenseed Ltd, Galera Therapeutics, Inc., Helix BioPharma, Golden Biotechnology Corporation, Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd., Panbela Therapeutics, Inc., GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, Roche, Prestige Biopharma Limited, Everfront Biotech Co., Ltd., XBiotech, Inc., Incyte Corporation, Ability Pharmaceuticals SL, Lokon Pharma, HCW Biologics, Amplia Therapeutics Limited, BioLineRx, Ltd., Taiho Pharmaceutical, Sanofi, Scandion Oncology, Nelum, Celldex Therapeutics, Merus N.V., Seagen Inc., GC Cell Corporation, MetiMedi Pharmaceuticals, Lumicell, Nuvation Bio Inc., ENB Therapeutics, BioNTech SE, Bayer, Genentech, Inc., Rise Biopharmaceuticals, Inc., Prestige Biopharma Limited, iOnctura, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Hengrui Pharmaceutical Co., Ltd., Hangzhou Neoantigen Therapeutics Co., Ltd., EUSA Pharma, Inc.,Agenus Inc., Arcus Biosciences, Inc., Amgen, Biomea Fusion, and others.
Key Pancreatic Cancer Pipeline Therapies: Pamrevlumab, Niraparib, CT041, APG-1387, BNT141, ENB003, NUV-868, MCLA-128, LUM015, tisotumab vedotin, OMT-111, tusamitamab ravtansine, SCO-101, NGM120, CDX-301, NLM-001, TAS 102, Olaptesed pegol, BL-8040, Gimatecan, AMP945, N-803, HCW9218, BLEX 404, delolimogene mupadenorepvec, Mitoxantrone Hydrochloride Liposome injection, ABTL0812, CBP501, Pemigatinib, SHR-1701, Fluzoparib, XB2001, Cabiralizumab, EF-009, SGT-53, ABBV-927, PBP1510, Vemurafenib, siG12D-LODER, Penpulimab, GC4711, GSK2256098, L-DOS47, SBP-101, Antroquinonol, LY3214996, Sintilimab, RP72,PBP1510, IOA-289, U87, MVT-5873, SHR-A1904, iNeo-Vac-P01, iNeo-Vac-P01, TQB2858, Siltuximab, AGEN1423, AB680, AMG 199, BMF-219, and others.
Dive deep into rich insights for pancreatic cancer research; visit @
New Treatment for Pancreatic Cancer
Table of Contents
For further information on pancreatic cancer prevention, reach out @
Pancreatic Cancer Drug Treatment
Related Reports
Pancreatic Cancer Epidemiology
Pancreatic Cancer Epidemiology Forecast
– 2032 report delivers an in-depth understanding of the disease, historical, and forecasted pancreatic cancer epidemiology in the 7MM.
Pancreatic Cancer Market
Pancreatic Cancer
Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key pancreatic cancer companies, including
FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, among others.
Advanced Pancreatic Cancer Market
Advanced Pancreatic Cancer
Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key advanced pancreatic cancer companies, including
AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, among others.
Advanced Pancreatic Cancer Pipeline
Advanced Pancreatic Cancer Pipeline Insight
– 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced pancreatic cancer companies, including
FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, among others.
Metastatic Pancreatic Cancer Market
Metastatic Pancreatic Cancer
Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key metastatic pancreatic cancer companies, including
Takeda Oncology, Salspera, Eli Lilly and Company, among others.
Metastatic Pancreatic Cancer Pipeline
Metastatic Pancreatic Cancer Pipeline Insight
– 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic pancreatic cancer companies, including
Takeda Oncology, Salspera, Eli Lilly and Company, among others.
Other Trending Oncology Reports
Follicular lymphoma
|
Indolent lymphoma
|
Severe Toxicities In Lymphoma
|
Marginal Zone Lymphoma
|
Vulvar Squamous Cell Carcinoma
|
Cholangiocarcinoma
|
Metastatic Cutaneous Squamous cell Carcinoma
|
Nasopharyngeal Carcinoma
|
Ductal Carcinoma in Situ
|
Oncolytic Virus Cancer Therapy
|
Cancer Cachexia
|
Intratumoral Cancer Therapies
|
Brain Cancer
Related Healthcare Blogs
Upcoming Oncology Drugs
Oncology Market Outlook
Future of Oncology Market
Related Cases Studies
Competitive Intelligence
Market Assessment
Product Assessment
Epidemiology Assessment
Related Healthcare Services
Healthcare Business Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
Fast TrackOrphan DrugClinical ResultImmunotherapy
11 Oct 2022
The prevalence of esophageal cancer has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing prevalence of cancer and the increase in research & development. The Companies developing the potential therapies in the last stage of development include Celgene,Jiangsu HengRui Medicine Co., Seagen, and several others.
LAS VEGAS, Oct. 11, 2022 /PRNewswire/ -- DelveInsight's
'
Esophageal Cancer Pipeline Insight – 2022
' report provides comprehensive global coverage of available, marketed, and pipeline esophageal cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the esophageal cancer pipeline domain.
Key Takeaways from the Esophageal Cancer Pipeline Report
DelveInsight's esophageal cancer pipeline report depicts a robust space with
80+ active players working to develop
90+ pipeline therapies for esophageal cancer treatment.
Leading esophageal cancer companies such as
Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others are evaluating new drugs for esophageal cancer treatment.
Key esophageal cancer pipeline therapies in various stages of development include
Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, AP 203, QEQ278, JAB-3312, DKN-01, AN0025, HR 070803,Oraxol, Sunitinib malate, Tiragolumab, iNeo Vac P01, Amivantamab, CA-4948, M1231, APX005M, DC-CIK, Margetuximab, Temozolomide, and others.
In
September 2022,
Daiichi Sankyo and
Sarah Cannon Research Institute (SCRI) announced that extended follow-up data from a phase I/II trial of
DS-7300, continued to show promising durable tumor response in patients with several types of heavily pretreated cancers including lung, prostate or esophageal cancer.A response rate of 32% (95% CI: 24-41) was observed with 38 responses (33 confirmed; 28%; 95% CI: 20-37) in 118 patients with various solid tumors including small cell lung cancer (SCLC), squamous non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC) or endometrial cancer receiving doses of DS-7300 ranging from 4.8 mg/kg to 16.0 mg/kg.
In
September 2022,
Integral Molecular, has
licensed a panel of monoclonal antibodies (MAbs) to
CARTEXELL, enabling CARTEXELL to develop CAR-T cell therapies using Integral Molecular's Claudin 18.2 (CLDN18.2) MAbs. Under the terms of the agreement, Integral Molecular will provide an exclusive worldwide license to CARTEXELL to use the panel of high-affinity, high-specificity, and fully humanized CLND18.2 MAbs for the development of CAR-T cell therapies against solid tumors including gastric, lung, pancreatic and esophageal cancers. CARTEXELL will be solely responsible for all research, development, and commercial activities.
In
August 2022,
BeiGene announced that the
Center for Drug Evaluation (CDE) of the China
National Medical Products Administration (NMPA) has accepted a
supplemental biologics license application (sBLA) for
tislelizumab in combination with chemotherapy as first-line treatment in patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
In
May 2022,
Shanghai Junshi Biosciences Co., Ltd, announced that the
China National Medical Products Administration (NMPA) has approved the
supplemental new drug application (sNDA) for
toripalimab in combination with paclitaxel and cisplatin in the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC). The sNDA was accepted by the NMPA in July 2021. This is the fifth indication approved for toripalimab in China and will benefit Chinese patients with advanced ESCC.
In
May 2022,
Bristol Myers Squibb, announced that the U.S.
Food and Drug Administration (FDA) has
approved both
Opdivo (nivolumab) (injection for intravenous use) in combination with fluoropyrimidine- and platinum-containing chemotherapy and
Opdivo plus Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status. The approvals are based on the Phase III CheckMate -648 trial, which evaluated Opdivo in combination with chemotherapy (n=321) and Opdivo plus Yervoy (n=325) each compared to chemotherapy alone (n=324), and was the largest Phase III trial of immunotherapy in first-line ESCC.
In
January 2022,
Lyell Immunopharma, Inc., announced that the U.S.
Food and Drug Administration (FDA) has cleared an
Investigational New Drug (IND) application to initiate a Phase I clinical trial for
LYL132, an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1) that the company is developing in collaboration with GSK.
Request a sample and discover the recent advances in esophageal cancer treatment @
Esophageal Cancer Pipeline Report
The esophageal cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage esophageal cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the esophageal cancer pipeline landscape.
Esophageal Cancer Overview
Esophageal cancer grows in the esophagus, the tube that connects the throat to the stomach. Tumors develop in the mucosa, the inner lining of the esophagus. Esophageal cancer is classified into two types, each with its own set of risk factors: Adenocarcinoma -Adenocarcinomas are cancers that begin in gland cells at the bottom of the esophagus. This is the most common type of esophageal cancer. It usually happens near the stomach. The exact esophageal cancer causes are not known.
Most esophageal cancer symptoms do not appear until cancer has progressed to an advanced stage, when it may be challenging to treat. Other, more common conditions can cause esophageal cancer symptoms. The most common esophageal cancer symptom is difficulty swallowing, particularly a sensation of food stuck in the chest.
There are several tests used for esophageal cancer diagnosis. The most common include endoscopy with biopsy and endoscopic ultrasonography.
Find out more about esophageal cancer drugs in development @
New Treatment for Esophageal Cancer
A snapshot of the Esophageal Cancer Pipeline Drugs mentioned in the report:
Learn more about the emerging esophageal cancer pipeline therapies @
Esophageal Cancer Clinical Trials
Esophageal Cancer Therapeutics Assessment
The
esophageal cancer pipeline report proffers an integral view of esophageal cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Esophageal Cancer Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment
By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
Therapeutics Assessment
By Molecule Type: Oligonucleotide, Peptide, Small molecule
Therapeutics Assessment
By Mechanism of Action: Prostaglandin E EP4 receptor antagonists, ERBB 2 receptor antagonists, Phosphorylation inhibitors, Antibody-dependent cell cytotoxicity, Apoptosis stimulants, CD40 antigen stimulants, Immunostimulants, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Epidermal growth factor receptor antagonists.
Key Esophageal Cancer Companies: Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL and others
Key Esophageal Cancer Pipeline Therapies: Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, AP 203, QEQ278, JAB-3312, DKN-01, AN0025, HR 070803,Oraxol, Sunitinib malate, Tiragolumab, iNeo Vac P01, Amivantamab, CA-4948, M1231, APX005M, DC-CIK, Margetuximab, Temozolomide and others.
Dive deep into rich insights for esophageal cancer drugs, visit @
Chemo Drugs for Esophageal Cancer Treatment
Table of Contents
For further information on the esophageal cancer pipeline therapeutics, reach out @
New Drug for Esophageal Cancer Treatment
Related Reports
Esophageal Cancer Market
Esophageal Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key esophageal cancer companies including
Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, among others.
Esophageal Cancer Epidemiology Forecast
Esophageal Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted esophageal cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Esophageal Squamous Cell Carcinoma Pipeline
Esophageal Squamous Cell Carcinoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key esophageal squamous cell carcinoma companies, including
BeiGene, AstraZeneca, Ipsen, Shire, Sanofi, Seagen, among others.
Esophageal Squamous Carcinoma Market
Esophageal Squamous Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key esophageal squamous carcinoma companies, including
BeiGene, AstraZeneca, Ipsen, Shire, Sanofi, Seagen, among others.
Esophageal Squamous Cell Carcinoma Epidemiology
Esophageal Squamous Cell Carcinoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted esophageal squamous cell carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Goitre Market
|
Thymus Cancer Market
|
US Healthcare Outlook Report
|
Venous Stenosis Market
|
Negative Pressure Wound Therapy Systems Market
|
Global Kinase Inhibitor in Autoimmune Diseases Market
|
Metrorrhagia Market
|
Dysfunctional Uterine Bleeding Market
|
Hypereosinophilic Syndrome Market
|
Age-related Vision Dysfunction Market
|
Dental Lasers Market
|
CRISPR Therapies Pipeline Insight
|
Cell And Gene Therapy For Multiple Myeloma Market
|
Drug Hypersensitivity Market
|
Dysthymia Market
|
Persistent Depressive Disorder Market
|
Cancer Vaccines Market
|
Weight Loss/Weight Management (Obesity) Market |
Food Allergy Market |
Obsessive-Compulsive Disorder Market |
Tumor Ablation Market |
Physiotherapy Equipment Market |
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market |
Anti-hypertension Market |
Radiofrequency Ablation Devices Market |
Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |
Gastro Intestinal Bleeding Market |
Trastuzumab Biosimilars Insight |
Varicose Veins Market |
Germ Cell Tumor Market |
Intracardiac Echocardiography Devices Market |
India Healthcare Report |
Crows Feet Market |
Seborrhoeic Dermatitis Market |
Injectable Drug Delivery Devices Market |
Structural Heart Devices Market |
Substance (Drug) Abuse Market |
Insulin Glargine Biosimilar Insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
Gene TherapyAntibodyBiosimilarOligonucleotideCell Therapy
100 Deals associated with iNeo-Vac-P01
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cholangiocarcinoma | Phase 1 | CN | 10 Oct 2023 | |
| Hepatocellular Carcinoma | Phase 1 | CN | 10 Oct 2023 | |
| Intestinal Neoplasms | Phase 1 | CN | 10 Oct 2023 | |
| Melanoma | Phase 1 | CN | 10 Oct 2023 | |
| Stomach Cancer | Phase 1 | CN | 10 Oct 2023 | |
| Esophageal Carcinoma | Phase 1 | CN | 02 Dec 2021 | |
| Pancreatic Cancer | Phase 1 | CN | 30 Mar 2021 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 07 Feb 2018 | |
| Locally Advanced Malignant Neoplasm | Phase 1 | CN | 07 Feb 2018 | |
| Colorectal Cancer | IND Approval | CN | 07 Apr 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
NCT03662815 (ASCO2022) Manual  | Phase 1 | 28 | GM-CSF+iNeo-Vac-P01 (had received RFA treatment within 6 months before scheduled for vaccination) | awngcuhaqn(nlsgqekkwc) = hceirxcqmy esfwscshxe (pggurzmpnx ) View more | Positive | 02 Jun 2022 | |
GM-CSF+iNeo-Vac-P01 (had not received RFA treatment within 6 months before scheduled for vaccination) | awngcuhaqn(nlsgqekkwc) = ubupkegyaj esfwscshxe (pggurzmpnx ) View more | ||||||
NCT03645148 (Pubmed) Manual | Phase 1 | 7 | ljacqchsht(vhezvybbri) = hsjbstqhez lkkbpjkida (gsselixklt ) View more | Positive | 13 Aug 2021 | ||
Phase 1 | 22 | jjxokhmzbi(pllimsjmxo) = wlynpwmvsk bwoediezxx (ugngoacwzv ) View more | Positive | 01 Sep 2020 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free